LPTX241220C6000
- 0.40
- 0.000.00%
Leap Therapeutics Newsroom
Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook
Leap Therapeutics | 8-K: Leap Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate
Leap Therapeutics: Cash Position Expected to Fund Operations Into 2Q 2026 >LPTX
Express News | Leap Therapeutics Q3 Operating Income USD -17.855 Million
Press Release: Leap Therapeutics Reports Third Quarter 2024 Financial Results
Leap Therapeutics 3Q Loss $18.2M >LPTX
Leap Therapeutics | 10-Q: Q3 2024 Earnings Report
Leap and Siro Unite to Unlock Total Sales Transparency With New Integration in SalesPro
Leap Therapeutics Completes Enrollment in Part B of DeFianCe Study
Express News | Leap Therapeutics Announces Completion of Enrollment in Part B of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients
Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Leap LLC Welcomes Jason Tillery as New Board Member: A Strategic Move to Enhance AI Capabilities
Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate, Cash And Cash Equivalents Totaled $78.5M At June 30, 2024, Expected To Fund Leap's Operating And Capital Expenditures Into Q2 Of 2026
Leap Therapeutics GAAP EPS of -$0.52 Misses by $0.09
Leap Therapeutics | 8-K: Leap Therapeutics Reports Second Quarter 2024 Financial Results
Express News | Leap Therapeutics: Net Proceeds From Financing, With Existing Cash, Expected to Fund Operating & Capital Expenditures Into Q2 2026